Report - Q3/FY2016 FINANCIALRESULTS - Astellas Pharma · Q3/FY15 Q3/FY16 2,865 2,889 (+0.8%) Q3/FY15 Q3/FY16 68.8 XTANDI and OAB products growth CRESEMBA contribution XTANDI growth Prografand

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form